JP2017520588A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017520588A5 JP2017520588A5 JP2017500822A JP2017500822A JP2017520588A5 JP 2017520588 A5 JP2017520588 A5 JP 2017520588A5 JP 2017500822 A JP2017500822 A JP 2017500822A JP 2017500822 A JP2017500822 A JP 2017500822A JP 2017520588 A5 JP2017520588 A5 JP 2017520588A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- carbonitrile
- pyrazole
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- IJCMHHSFXFMZAI-UHFFFAOYSA-N 6-amino-1,3-dimethyl-4-[4-(trifluoromethyl)phenyl]-4H-pyrano[2,3-c]pyrazole-5-carbonitrile Chemical compound C1=2C(C)=NN(C)C=2OC(N)=C(C#N)C1C1=CC=C(C(F)(F)F)C=C1 IJCMHHSFXFMZAI-UHFFFAOYSA-N 0.000 claims 1
- AZBZPRFEFCPULP-UHFFFAOYSA-N 6-amino-3,4-bis(4-methoxyphenyl)-1-phenyl-4H-pyrano[2,3-c]pyrazole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1C(C#N)=C(N)OC2=C1C(C=1C=CC(OC)=CC=1)=NN2C1=CC=CC=C1 AZBZPRFEFCPULP-UHFFFAOYSA-N 0.000 claims 1
- CVBGNGJDVPGNQF-UHFFFAOYSA-N CN1N=C(C)C2=C1OC(N)=C(C#N)C2C1=CC=C2OCCOC2=C1 Chemical compound CN1N=C(C)C2=C1OC(N)=C(C#N)C2C1=CC=C2OCCOC2=C1 CVBGNGJDVPGNQF-UHFFFAOYSA-N 0.000 claims 1
- 206010027476 Metastasis Diseases 0.000 claims 1
- IOBYFCZQHVVRQS-UHFFFAOYSA-N NC1=C(C(C2=C(N(N=C2C2=CC=CC=C2)C)O1)C1=CC=C(C=C1)OC(F)(F)F)C#N Chemical compound NC1=C(C(C2=C(N(N=C2C2=CC=CC=C2)C)O1)C1=CC=C(C=C1)OC(F)(F)F)C#N IOBYFCZQHVVRQS-UHFFFAOYSA-N 0.000 claims 1
- 102000004357 Transferases Human genes 0.000 claims 1
- 108090000992 Transferases Proteins 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002686 geranylgeranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Claims (7)
-
ピラノ[2,3−c]ピラゾール−5−カルボニトリル
からなる群より選択される化学構造を有する化合物、或いは、その薬学的に許容可能なエナンチオマー、ジアステレオマー、ラセミ体、又は塩。 - 請求項1に記載の少なくとも1つの化合物と少なくとも1つの医薬賦形剤を含む医薬組成物。
- 請求項2に記載の医薬組成物を含む医薬パッケージ。
- 請求項2に記載の医薬組成物と、該組成物についての処方情報と、容器とを含む、医薬キット。
- 癌の予防、治療、改善、又は癌の転移予防のための請求項2に記載の医薬組成物。
- 前記医薬組成物が、治療に効果的な量の前記化合物と、薬学的に許容可能な担体とから本質的になる、非経口投与又は経口投与に適した単相医薬組成物である、請求項2又は5に記載の医薬組成物。
- 前記医薬組成物が、1つ若しくは複数のI型ゲラニルゲラニルトランスフェラーゼ(GGTアーゼ−I)阻害剤、外科手術、化学療法、放射線療法、免疫療法、又はそれらの組合せと併せて投与されることによって更に特徴付けられる、請求項2、5、又は6に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462022946P | 2014-07-10 | 2014-07-10 | |
US62/022,946 | 2014-07-10 | ||
PCT/US2015/040021 WO2016007905A1 (en) | 2014-07-10 | 2015-07-10 | Anti-cancer compounds target ral gtpases and methods of using the same |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020036345A Division JP7102012B2 (ja) | 2014-07-10 | 2020-03-04 | Ral GTPアーゼを標的とする抗癌化合物及びそれを使用する方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017520588A JP2017520588A (ja) | 2017-07-27 |
JP2017520588A5 true JP2017520588A5 (ja) | 2018-08-16 |
JP6672255B2 JP6672255B2 (ja) | 2020-03-25 |
Family
ID=55064987
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017500822A Active JP6672255B2 (ja) | 2014-07-10 | 2015-07-10 | Ral GTPアーゼを標的とする抗癌化合物及びそれを使用する方法 |
JP2020036345A Active JP7102012B2 (ja) | 2014-07-10 | 2020-03-04 | Ral GTPアーゼを標的とする抗癌化合物及びそれを使用する方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020036345A Active JP7102012B2 (ja) | 2014-07-10 | 2020-03-04 | Ral GTPアーゼを標的とする抗癌化合物及びそれを使用する方法 |
Country Status (9)
Country | Link |
---|---|
US (4) | US10202397B2 (ja) |
EP (2) | EP3166609B1 (ja) |
JP (2) | JP6672255B2 (ja) |
KR (3) | KR20170018084A (ja) |
CN (1) | CN106604731B (ja) |
AU (2) | AU2015287567A1 (ja) |
CA (1) | CA2954560C (ja) |
IL (1) | IL249959A0 (ja) |
WO (1) | WO2016007905A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2954560C (en) | 2014-07-10 | 2021-12-28 | The Regents Of The University Of Colorado, A Body Corporate | Substituted 6-amino-1,3-dissubstituted-4-phenyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile compounds and pharmaceutical compositions thereof as ral gtpase inhibitors for treating cancer or its metastasis |
WO2016145252A1 (en) | 2015-03-10 | 2016-09-15 | The Trustees Of Princeton University | Shmt inhibitors |
US10077273B2 (en) | 2016-09-14 | 2018-09-18 | The Trustees Of Princeton University | SHMT inhibitors |
CN109305972B (zh) * | 2018-09-27 | 2021-07-09 | 广州医科大学 | 一种二氢吡喃并吡唑类化合物及其制备方法和应用 |
EP3766544A1 (en) * | 2019-07-18 | 2021-01-20 | Centre Hospitalier Regional Universitaire de Lille | Novel pyrazolone derivatives as pd-1/pd-l1 interaction inhibitors |
WO2022238763A1 (en) | 2021-05-10 | 2022-11-17 | Novalum S.a. | Cathode current collector bar of an aluminium production cell |
CN114632147B (zh) * | 2021-11-09 | 2024-04-30 | 南京大学 | 人类受试者心肌病的治疗 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4555396A (en) | 1982-12-22 | 1985-11-26 | Eastman Kodak Company | Use of pyrylium and thiapyrylium compounds as biological stains |
US5750550A (en) | 1995-09-15 | 1998-05-12 | Sanofi | 2-(pyrazol-5-yl-oxymethyl)-1,2-benzisothiazol-3 (2H)-One 1, 1-dioxides and compositions and method of use thereof |
JPH10279480A (ja) | 1997-04-07 | 1998-10-20 | Mitsubishi Chem Corp | 皮膚組織障害の予防・治療剤 |
DE19910363B4 (de) | 1998-03-10 | 2007-08-30 | Mitsubishi Paper Mills Ltd. | Positives, lichtempfindliches bebilderbares Element |
CA2702148C (en) | 1999-01-06 | 2014-03-04 | Genenews Inc. | Method of profiling gene expression in a human subject having an infectious disease |
WO2005020784A2 (en) | 2003-05-23 | 2005-03-10 | Mount Sinai School Of Medicine Of New York University | Surrogate cell gene expression signatures for evaluating the physical state of a subject |
AU2004262369A1 (en) * | 2003-07-29 | 2005-02-10 | Bristol-Myers Squibb Company | Biomarkers of cyclin-dependent kinase modulation |
WO2006126625A1 (ja) | 2005-05-25 | 2006-11-30 | Mitsubishi Tanabe Pharma Corporation | ピラゾロン誘導体を含む医薬 |
US7826982B2 (en) | 2005-07-29 | 2010-11-02 | Children's Hospital Medical Center | Method of identifying inhibitors using a 3-D structure of RAC-1 GTPASE |
WO2007026024A2 (en) | 2005-09-02 | 2007-03-08 | Tibotec Pharmaceuticals Ltd. | Benzodiazepines as hcv inhibitors |
US20090221568A1 (en) * | 2005-11-04 | 2009-09-03 | Jared Shaw | Synthesis of Inhibitors of FtsZ |
US20070203224A1 (en) | 2006-01-09 | 2007-08-30 | University Of Southern California | Small-molecules for treating cancer and abnormal cell proliferation disorders |
WO2008143894A2 (en) | 2007-05-14 | 2008-11-27 | Dana-Farber Cancer Institute, Inc. | Phosphorylated rala |
CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
JPWO2011010715A1 (ja) * | 2009-07-24 | 2013-01-07 | 国立大学法人 東京大学 | Pr−Set7阻害剤 |
WO2011035143A2 (en) | 2009-09-17 | 2011-03-24 | The Regents Of The University Of Michigan | Methods and compositions for inhibiting rho-mediated diseases and conditions |
US8673913B2 (en) | 2009-11-13 | 2014-03-18 | Case Western Reserve University | SHP-2 phosphatase inhibitor |
US20120214824A1 (en) * | 2010-12-08 | 2012-08-23 | Bradley Tait | Proteostasis regulators |
US9200046B2 (en) * | 2011-06-29 | 2015-12-01 | Cornell University | Reporter system for high throughput screening of compounds and uses thereof |
US9353121B2 (en) | 2011-12-21 | 2016-05-31 | The Regents Of The University Of Colorado, A Body Corporate | Anti-cancer compounds targeting Ral GTPases and methods of using the same |
WO2013096852A1 (en) * | 2011-12-21 | 2013-06-27 | The Regents Of The University Of Colorado | Biomarkers of cancer |
WO2013152313A1 (en) | 2012-04-05 | 2013-10-10 | The Regents Of The University Of California | Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition |
US9480259B2 (en) | 2012-06-06 | 2016-11-01 | Basf Se | Pyrazolopyrans having herbicidal and pharmaceutical properties |
CN103910737B (zh) * | 2014-03-25 | 2016-08-17 | 浙江师范大学 | 手性的1,4-二氢吡喃(2,3-c)吡唑衍生物及其合成方法和应用 |
CA2954560C (en) | 2014-07-10 | 2021-12-28 | The Regents Of The University Of Colorado, A Body Corporate | Substituted 6-amino-1,3-dissubstituted-4-phenyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile compounds and pharmaceutical compositions thereof as ral gtpase inhibitors for treating cancer or its metastasis |
WO2016205460A1 (en) * | 2015-06-16 | 2016-12-22 | Nantbioscience, Inc. | Polycyclic derivatives targeting ral gtpases and their therapeutical applications |
-
2015
- 2015-07-10 CA CA2954560A patent/CA2954560C/en active Active
- 2015-07-10 KR KR1020177002960A patent/KR20170018084A/ko active Application Filing
- 2015-07-10 KR KR1020207008228A patent/KR20200034824A/ko not_active Application Discontinuation
- 2015-07-10 US US15/324,629 patent/US10202397B2/en not_active Ceased
- 2015-07-10 JP JP2017500822A patent/JP6672255B2/ja active Active
- 2015-07-10 WO PCT/US2015/040021 patent/WO2016007905A1/en active Application Filing
- 2015-07-10 AU AU2015287567A patent/AU2015287567A1/en not_active Abandoned
- 2015-07-10 EP EP15819681.6A patent/EP3166609B1/en active Active
- 2015-07-10 EP EP20162079.6A patent/EP3686202A1/en active Pending
- 2015-07-10 KR KR1020197005669A patent/KR102093848B1/ko active IP Right Grant
- 2015-07-10 CN CN201580047117.8A patent/CN106604731B/zh active Active
-
2017
- 2017-01-06 IL IL249959A patent/IL249959A0/en unknown
-
2019
- 2019-01-07 US US16/241,587 patent/US10676480B2/en active Active
- 2019-08-27 US US16/553,092 patent/USRE48557E1/en active Active
-
2020
- 2020-03-04 JP JP2020036345A patent/JP7102012B2/ja active Active
- 2020-04-30 US US16/863,867 patent/US11472812B2/en active Active
- 2020-11-27 AU AU2020277293A patent/AU2020277293B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2017520588A5 (ja) | ||
JP2016040288A5 (ja) | ||
JP2015505296A5 (ja) | ||
ZA202007671B (en) | Pharmaceutical combination, composition, and combination formulation containing glucokinase activator and biguanide hypoglycemic drug as well as preparation method and use thereof | |
JP2017505293A5 (ja) | ||
MX2019011904A (es) | Composicion farmaceutica que contiene agonista de mor y agonista de kor, y sus usos. | |
JP2011500550A5 (ja) | ||
UA109698C2 (xx) | Похідні азаіндазолу або діазаіндазолу як медикамент | |
JP2014513110A5 (ja) | ||
EA201591291A1 (ru) | Производные пиримидона и их применение в лечении, облегчении или профилактике вирусного заболевания | |
WO2012147107A3 (en) | Novel & improved processes for preparing indoline derivatives and its pharmaceutical composition | |
JP2010525056A5 (ja) | ||
JP2011509309A5 (ja) | ||
JP2008538582A (ja) | 精神病性障害の治療または予防のための新規の治療的組み合わせ | |
JP2016510326A5 (ja) | ||
JP2016539157A5 (ja) | ||
JP2017528473A5 (ja) | ||
HRP20210158T1 (hr) | Postupak i sustav za premještanje fluida iz posude za opskrbu u komponentu za isporuku | |
JP2020515645A5 (ja) | ||
PH12015501945A1 (en) | Formulations of organic compounds | |
JP2016514688A5 (ja) | ||
JP2020515523A5 (ja) | ||
JP2018535235A5 (ja) | ||
JP2014532063A5 (ja) | ||
EA201592247A1 (ru) | 4-(5-(4-ХЛОРОФЕНИЛ)-2-(2-ЦИКЛОПРОПИЛАЦЕТИЛ)-1,4-ДИМЕТИЛ-1H-ПИРРОЛ-3-ИЛ)БЕНЗОЛСУЛЬФОНАМИД В КАЧЕСТВЕ МОДУЛЯТОРА АЛЬФА-7 nAChR |